Potent and Orally Bioavailable BCL6 PROTAC® Degraders Demonstrate Efficacy in Pre-Clinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)
First-in-human safety and activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in ER+/HER2-locally advanced or metastatic breast cancer
Heterobifunctional Degrader Molecules that lead to the clearance of Pathologic Proteins in Neurodegeneration
Discovery of ARV-110, a first in class androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer
The Discovery of ARV-471, an Orally Bioavailable Estrogen Receptor Degrading PROTAC® for the Treatment of Patients with Breast Cancer
